AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new Otezla (apremilast) data, along with findings on the unmet need for patients with plaque...

Related Keywords

Massachusetts , United States , Japan , Puerto Rico , Boston , America , Japanese , American , Michael Strapazon , Palmoplantar Pustulosis , Jessica Akopyan , Kyowa Kirin Co Ltd , Amgen , Data On File At Amgen Inc , Global Development , Drug Administration , Beigene Ltd , Exchange Commission , American Academy Of Dermatology , Therapeutics Inc , National Psoriasis Foundation , Teneobio Inc , American Academy , Primal Kaur , Corevita Psoriasis , Presentation Times , Japanese Patients With Palmoplantar Pustulosis , Results From , Oral Presentation , Moderate Psoriasis , Subgroup Analysis Stratified , Satisfaction Levels From , Patients With Mild , Moderate Psoriasis Assessed , Physician Global Assessment , Body Surface Area Composite Tool , Post Hoc Analysis From , Special Areas , Patient Quality Of Life Outcomes , Depression Screening , Findings From , Between Skin Involvement , Disease Burden , Moderate Plaque Psoriasis , Real World Findings From Corevita Psoriasis , Severity Index , Static Physician , Global Assessment , Body Surface Area , Psoriasis Area , North America , Psoriatic Arthritis , Full Prescribing , Dow Jones Industrial Average , Best Workplaces , Great Place , Five Prime Therapeutics , Accessed September ,